FDA TPLC Review Centers on Coagulation Control Plasma for In Vitro Testing
The FDA Total Product Life Cycle entry for plasma, coagulation control places this product squarely in the regulatory category of a multipurpose system for in vitro coagulation studies. The device carries product code GGN, falls under regulation 21 CFR 864.5425, and is classified as a Class II device. In practical terms, this is the kind of laboratory material that anchors clotting assay calibration and quality assurance rather than direct patient treatment, yet its accuracy still shapes bedside decisions in anticoagulation management, bleeding workups, and hemostasis monitoring.
The listing is sparse on promotional language and rich in regulatory footprint. Multiple manufacturers have received substantially equivalent determinations for related control plasma products, including AALTO Scientific, Affinity Biologicals, Cliniqa, Diagnostica Stago, Diagnostics Stago S.A.S., George King Bio-Medical, Instrumentation Laboratory, International Technidyne Corp., and Maine Standards Company. For laboratory medicine, that pattern matters because it signals a mature product category with repeated submissions around similar control materials rather than a single isolated device pathway.
Regulatory Clearance Patterns Across Multiple Manufacturers
The premarket record shows a cluster of cleared control products rather than a one-off approval history. Several entries are linked to Hemosil-branded controls and related plasma materials, including low abnormal, normal, high abnormal, routine control levels, low-molecular-weight heparin control plasma, INR validation, ISI calibration, and lupus anticoagulant positive and negative controls. Those product names reveal the underlying clinical task: keeping coagulation assays anchored to known reference behavior so that a laboratory can interpret whether a prolonged clotting time reflects biology, drug effect, or assay drift.
The regulatory category also explains why the device sits outside the spotlight that surrounds implantables, life-support systems, or high-risk therapeutics. Still, coagulation controls can have real consequences when they are mishandled. An inaccurate control result can distort interpretation of prothrombin time, activated partial thromboplastin time, lupus anticoagulant testing, or INR validation, creating the kind of downstream error that shows up only when a clinician is forced to reconcile an unexpected bleeding history, thrombotic risk, or anticoagulant response.
A laboratory control plasma is only as reliable as the process used to handle it.
MDR Reports Point to Procedure and Human Factors, Not a Device Defect Signal
The adverse event profile in the TPLC record is limited but instructive. MDR counts are listed for 2016, 2017, and 2018, with 9 reports in 2016, 11 in 2017, and 4 in 2018. The device problem categories are dominated by Improper or Incorrect Procedure or Method, followed by Adverse Event Without Identified Device or Use Problem, Human Factors Issue, and Use of Device Problem. One report also falls under device handling problem, and one cites a missing value reason.
The patient problem field is even more striking. Laceration(s) appears in 21 MDRs, with 2 additional reports listing injury and 1 listing no known impact or consequence to the patient. The structure of those reports suggests that the safety burden in this dataset is tied more to handling, technique, or procedural execution than to an intrinsic performance flaw in the plasma control itself. In laboratory settings, that can happen when a device is mishandled, opened incorrectly, prepared improperly, or used outside the intended workflow, turning a relatively stable control material into a source of exposure or specimen-related harm.
Those events do not map neatly onto a classic pharmacovigilance story, but they still matter clinically. Coagulation testing sits at the intersection of laboratory procedure and anticoagulation decision-making, so a handling error can ripple into delayed treatment, misread assay values, or repeat testing that consumes time and blood volume. When the reported patient harms are mostly lacerations, the immediate concern shifts to packaging, sharps exposure, and operator technique rather than assay toxicity.
What the FDA Record Reveals About Coagulation Assay Quality
This TPLC profile is best read as a reminder that quality control materials are part of the diagnostic chain of custody. A control plasma used in coagulation studies does not diagnose disease on its own, but it verifies that the instrument, reagents, and workflow are functioning inside acceptable bounds. That is central to laboratories that support evaluation of bleeding disorders, heparin monitoring, lupus anticoagulant testing, and INR-related anticoagulant surveillance.
The repeated substantially equivalent findings across manufacturers also point to a market where equivalence, consistency, and assay compatibility are the core regulatory questions. Differences among products may matter in calibration, sensitivity, or intended assay range, but the FDA record provided here does not supply comparative performance claims. It does, however, show a long-standing demand for standardized control materials that laboratories can use to check whether coagulation testing systems remain trustworthy from one run to the next.
A short MDR trail does not erase the clinical importance of the product class. If anything, it shows how much of laboratory medicine depends on disciplined technique, validated methods, and careful interpretation of control material behavior. In coagulation testing, a small procedural failure can become a large diagnostic problem, especially when anticoagulant management or bleeding risk hinges on a single assay result.
The record leaves one major gap: it does not provide the underlying circumstances for the MDR reports, nor does it describe the specific recall entry beyond the manufacturer name and event listing. Without those details, the safest reading is narrow and factual — coagulation control plasma remains a routine but essential laboratory device category, one in which human factors and procedural handling account for much of the documented safety signal.